Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label, Randomized Phase 3 Clinical Study to Assess Efficacy and Safety of Bulevirtide in Patients With Chronic Hepatitis Delta
Conditions
Interventions
Bulevirtide
Locations
19
United States
New York University School of Medicine, an administrative unit of New York University, an education corporation
New York, New York, United States
Cornell University Well Madical College
New York, New York, United States
Universitätsklinikum Essen (AoR), Klinik für Gastroenterologie und Hepatologie
Essen, Germany
Universitätsklinikum Frankfurt Medizinische Klinik 1
Frankfurt am Main, Germany
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie und Endokrinologie
Hanover, Germany
Start Date
April 17, 2019
Primary Completion Date
November 26, 2020
Completion Date
August 8, 2024
Last Updated
August 22, 2025
NCT05861674
NCT05953545
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions